Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Non Operating Income: 2016-2025

Historic Non Operating Income for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to -$3.5 million.

  • Tg Therapeutics' Non Operating Income rose 57.68% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.3 million, marking a year-over-year increase of 38.18%. This contributed to the annual value of -$16.3 million for FY2024, which is 115.76% down from last year.
  • Per Tg Therapeutics' latest filing, its Non Operating Income stood at -$3.5 million for Q3 2025, which was up 11.90% from -$3.9 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Non Operating Income peaked at $3.6 million during Q1 2025, and registered a low of -$8.2 million during Q3 2024.
  • In the last 3 years, Tg Therapeutics' Non Operating Income had a median value of -$2.3 million in 2024 and averaged -$2.2 million.
  • As far as peak fluctuations go, Tg Therapeutics' Non Operating Income soared by 434.39% in 2023, and later crashed by 385.62% in 2024.
  • Tg Therapeutics' Non Operating Income (Quarterly) stood at -$391,000 in 2021, then tumbled by 138.36% to -$932,000 in 2022, then plummeted by 65.34% to -$1.5 million in 2023, then crashed by 191.76% to -$4.5 million in 2024, then soared by 57.68% to -$3.5 million in 2025.
  • Its last three reported values are -$3.5 million in Q3 2025, -$3.9 million for Q2 2025, and $3.6 million during Q1 2025.